Sipuleucel-T: Prototype for development of anti-tumor vaccines.
about
The Dichotomy of Tumor Exosomes (TEX) in Cancer Immunity: Is It All in the ConTEXt?Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growthIgE-based immunotherapy of cancer: challenges and chances.CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.Expanding the targets available to therapeutic antibodies via novel disease-specific markers.State of the art in tumor antigen and biomarker discovery.Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8⁺ T Cells that Protect Against Subcutaneous B16-OVA Melanoma.Current status of multiple antigen-presenting peptide vaccine systems: Application of organic and inorganic nanoparticles.Cancer vaccines inducing antibody production: more pros than cons.TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells.Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination.Prostate cancer vaccines in clinical trials.Ex vivo antigen-pulsed PBMCs generate potent and long lasting immunity to infection when administered as a vaccine.19F-perfluorocarbon-labeled human peripheral blood mononuclear cells can be detected in vivo using clinical MRI parameters in a therapeutic cell setting.
P2860
Q26773307-13B68AB4-C4EE-41FD-B644-B9A1310CAD7AQ28386614-81B1A526-0D68-4D69-837F-3DC8FAA69DBEQ33619979-CC5F392C-2EB8-4670-953F-80799E326AC6Q35077753-6D41EC42-3EDD-4CC1-91DC-5B6F4EF00061Q35128716-0DA29C89-E836-4D9B-8C67-21BB407DAFF8Q36119688-A5BF932F-209E-49E5-B24F-123A010395ECQ37132800-72FE6448-95D4-4912-9C16-85626507AA74Q37539236-282285FB-3498-4FA2-ABBA-C5F3430CFFD5Q37921384-74F40AAE-E83C-4133-9409-623C371573AEQ37932519-62CB4C56-5CD7-4C90-A64F-AAEBC4311754Q37952806-64565685-5C23-4BE1-A5B7-7809FC33DBB5Q37962075-F850753F-CD20-4FF7-A7B5-F898E3D6EB59Q38002844-529DC4D0-9505-4E61-8067-0AB3347E33E8Q38036690-068DA363-549B-4064-AB5A-DB5DDA1B59DDQ40379071-C28E17D6-AB5E-4506-A558-CBC8428DC3D8Q48507624-925ACE00-F5F8-47C6-AA78-E94797812E29
P2860
Sipuleucel-T: Prototype for development of anti-tumor vaccines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sipuleucel-T: Prototype for development of anti-tumor vaccines.
@en
Sipuleucel-T: Prototype for development of anti-tumor vaccines.
@nl
type
label
Sipuleucel-T: Prototype for development of anti-tumor vaccines.
@en
Sipuleucel-T: Prototype for development of anti-tumor vaccines.
@nl
prefLabel
Sipuleucel-T: Prototype for development of anti-tumor vaccines.
@en
Sipuleucel-T: Prototype for development of anti-tumor vaccines.
@nl
P2860
P1476
Sipuleucel-T: Prototype for development of anti-tumor vaccines.
@en
P2093
Estrella Carballido
Mayer Fishman
P2860
P2888
P304
P356
10.1007/S11912-011-0152-5
P577
2011-04-01T00:00:00Z